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Abstract: The δ-opioid receptor is sensitive to ligand geometry. In order to as-
sist the synthesis of new δ-selective opioid ligands, the structure elements of 
δ-selective opioid ligands necessary for their effective binding were investi-
gated. The automated docking procedure with a flexible ligand was used to si-
mulate the binding of 17 δ-selective ligands to the δ-receptor. It was found that 
voluminous N-alkyl groups reduce the binding potency of naltrindole derivati-
ves by preventing the ligands from adopting the preferred conformation in the 
receptor. This was confirmed by enantiospecific binding of chiral compounds 
where only one enantiomer adopts the naltrindole-like preferred conformation 
in the binding pocket. Voluminous groups replacing the hydroxyl group in the 
3-hydroxybenzyl fragment of naltrindole analogs reduce the binding potency 
due to unfavorable steric interactions with the receptor. The two diastereoiso-
mers of the potent δ-opioid ligand SNC80 confirmed the preferred binding con-
formation and the major receptor–ligand interactions. 
Keywords: molecular modeling; δ-opioid receptor; ligand–receptor interac-
tions; docking simulation. 
INTRODUCTION 
The δ-opioid receptor is an especially attractive target for the development of 
new drugs for the control of pain. Compared to other opioid or opioid-like re-
ceptors, δ-opioid selective drugs have some advantages, including: greater relief 
of naturopathic pain, reduced respiratory depression and constipation, and re-
duced potential for the development of physical dependence.1 Only one δ recep-
tor has been cloned to date;1,2 but several models of this receptor are available in 
the literature.3 These models are consistent with a vast sample of published bio-
physical and other experimental data3 but experimental data on the structure of 
any of the opioid receptors are unavailable. Considering the possible effects of 
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different media (the difference in the rhodopsine structure determined in the crys-
tal state4 and in solution5) and the obvious importance of the exact position of the 
amino acid residues6 which are different in different proteins, the available mo-
dels may be considered reliable opioid receptor representatives if they are ca-
pable of reproducing point mutation studies and other experimental data. 
There is experimental evidence that interaction of peptidic ligands with re-
ceptors are different from that of small ligands.7 Since small organic molecules 
as possible ligands of the δ-opioid receptor were our target, this study is limited 
to non-peptidic ligands of the δ-receptor, Table I. 
The region of a δ-opioid receptor involved in ligand binding and mediation of 
receptor function were identified by: a) construction of chimeric receptors con-
taining sequences from μ- or κ-opioid receptors,8 b) site-directed mutagenesis of 
specific amino acid residues9 and c) construction of truncated mutant receptors.10 
The site-directed mutagenesis experiments9a showed that Asp128 does not 
participate in the formation of a salt bridge between a ligand and the receptor, but 
it does contribute to the stabilization of the binding pocket. Some highly selective 
non-peptidic δ-ligands were moderately affected9b by mutations of the amino 
acids: Tyr129Phe, Trp274Ala and Tyr308Phe, indicating that these aromatic re-
sidues might be a part of the opioid binding domain. Chimeric receptors and the 
alanine scan method were used8b to show that Val296 and Val297 of the EC3 
loop are important for the binding of the δ-selective ligand SNC80. Leu295 and 
Ala298 of EC3 were important for the binding of naltrindole. The amino acids 
Trp284 (TM6 – transmembrane helix 6) and Ser312 (TM7 – trans membrane he-
lix 7) were important for both compounds, although to a lesser degree. Point mu-
tations performed on a mutant receptor emphasized the importance of Leu300, 
Ala298, Ala299 amino acids. Val281 had a moderate effect on ligand binding.8d 
It was found9c that Tyr308Phe mutation increased the binding. This amino acid, 
together with His278 (TM6) was suggested9c to participate in interactions 
[Asp128 (TM3)–Tyr308 (TM7) and Tyr129 (TM3)–His278 (TM6)] that maintain 
the δ-receptor in an inactive conformation. The model of the δ-opioid receptor 
showing important amino acids is presented in Fig. 1. 
In this study, the docking of a series of δ-opioid-selective ligands to a model 
of the human δ-receptor available in literature3a is reported. It is the model of an 
active form of the receptor, although the entire concept of active and inactive re-
ceptors has recently been questioned. Contrary to some earlier findings,11 recent 
X-ray studies12 on rhodopsine demonstrated that the transformation from the 
ground state to the photoactivated intermediate state involved minor changes in 
the receptor structure. It was suggested12 that the rigid inactive conformation of 
the receptor becomes more relaxed upon activation. It was also suggested12 that 
one receptor model may be used in docking calculations of both agonists and an-
tagonists. 
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TABLE I. Names and structures of the compounds 1–17 
Compound Name Structure 
1 Naltrindole, NTI 
N
+
N
HO
OH
OH
H
 
 Naltrindole derivatives 
N
+
N
HO
OH
R
OH
H
 
2 Oxymorphindole, R: CH3 
3 
R:
4 
R:
5 
R:
6 R: ; R1: CH3; R2: H 
N
+
N
H
OH
R
OR2
OR1
H
3
4
 
7 R: ; R1: CH3; R2: CH3 
8 R: ; R1: H; R2: CH3 
9 R: CH3; R1: CH3; R2: H 
10 R: CH3; R1: CH3; R2: CH3 
11 R: CH3; R1: H; R2: CH3 
12 (+)-4-[(αS)-α-((2S,5R)-4-Allyl-2,5-dimethyl-
1-piperazinyl)-3-methoxybenzyl]-N,N-di-
ethylbenzamide 
N
N
+
H
O
N
OMe
H
 
13 (–)-4-[(αR)-α-((2R,5S)-4-Allyl-2,5-dimethyl-
1-piperazinyl)-3-methoxybenzyl]-N,N-di-
ethylbenzamide 
N
N
+
H
H
O
N
OMe
 
14 (+)-3-[(2S,6R)-1,2,3,4,5,11-Hexahydro-3-
methyl-2,6-methano-6H-azocino[4,5-b]in-
dol-6-yl]phenol 
N
+
N
H
OH
H
2
6
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TABLE I. Continued 
Compound Name Structure 
15 (–)-3-[(2R,6S)-1,2,3,4,5,11-Hexahydro-3-methyl-
2,6-methano-6H-azocino[4,5-b]- 
indol-6-yl]phenol 
N
+
N
H
OH
H
2 6
 
16 (+)-3-[(2S,6R)-1,2,3,4,5,11-Hexahydro-3-(2-
phenylethyl)-2,6-methano-6H-azocino[4,5-b]in-
dol-6-yl]phenol 
N
+
N
H
OH
H
1
5
 
17 (–)-3-[(2R,6S)-1,2,3,4,5,11-Hexahydro-3-(2-
phenylethyl)-2,6-methano-6H-azocino[4,5-b]in-
dol-6-yl]phenol 
N
+
N
H
OH
H
1
5
 
The goal of the present work was to find and compare the binding con-
formations of δ-selective ligands and to identify the structural fragments the mo-
difications of which may increase the binding and perhaps activation of a δ-re-
ceptor. 
COMPUTATIONAL METHODS 
All computations were performed using a P4/Celeron at 1.5 GHz. The employed δ-recep-
tor model was taken from the literature.3a The receptor model was treated as rigid. The auto-
mated flexible ligand docking experiments were realized with the AutoDock 3.0.5. program.13 
The starting geometries, with a protonated ring nitrogen,14 were built using the HyperChem 
program15 and subsequently optimized using the semi-empirical AM1 method of the same 
program. The 60×60×60 grid was centered on one of the Asp128 oxygen atoms. The La-
marckian genetic algorithm (LGA) was used in all docking calculations. The docking process 
was performed in 250 LGA runs; the initial position of the ligand was random. The population 
was 50, the maximum number of generations was 27000 and the maximum number of energy 
evaluations was 2.5×106. The resultant ligand orientations and conformations were scored 
based on the binding energies (the cutoff value for the energies was 16.8 kJ/mol), and they 
were further evaluated based on the vicinity to important amino acids, found experimentally to 
be located in the binding site of the δ-selective non peptidic ligands. The clusters were ranked 
in order of increasing binding energy. The lowest binding energy conformations of all the 
selected clusters were analyzed in terms of their distances to the important amino acids. The 
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lowest binding energy conformation with the maximal number of close contacts to the 
important amino acids is referred to as the preferred conformation. 
 
(a) 
 
(b) 
Fig. 1. a) Serpentine model of the δ-opioid 
receptor. Important amino acids are in yel-
low (mutagenesis experiments); b) 3D model 
of the δ-opioid receptor with important ami-
no acids. 
RESULTS AND DISCUSSION 
Despite apparent structural differences, all the studied δ-selective com-
pounds have similar 3D geometries (Table I), consisting of a protonated piperi-
dine (or piperazine) ring and two aromatic rings. These three structural elements 
may adopt similar spatial positions in different ligand-receptor complexes, but 
may, as well, occupy different positions and orientations within the receptor. 
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Automated docking of compound 1 to the δ-opioid receptor model resulted 
in several plausible docking orientations and conformations for the ligand. The 
resulting ligand orientations and conformations were scored based on the values 
of the binding energies and by the number of close contacts to the receptor amino 
acids known to form the binding pocket within the δ-receptor, Fig. 1. Based on 
these criteria, the preferred conformation of compound 1 in the binding pocket of 
the δ-receptor model has a binding energy (Eb = –40.3 kJ/mol) 6.3 kJ/mol above 
the global minimum conformation. Its orientation is very similar to the one pro-
posed earlier, and follows the “message–address concept”,16 Figs. 2 and 3. 
 
Fig. 2. Ligands: 1 (yellow), 2 (green) and 
3 (pink) in the binding pocket. 
Fig. 3. Ligands: 1 (yellow), 6 (gray), 7 (orange) 
and 8 (blue) in the binding pocket. 
The protonated piperidine and the phenolic component form the “message” 
moiety related to ligand binding and the indolic component represents the “ad-
dress” moiety and determines ligand selectivity besides binding. According to the 
docking results, the “message” moiety interacts (within 0.4 nm) with Asp128, 
through salt bridge formation (+NH⋅⋅⋅O– distance 0.27 nm), with Tyr129 of TM3 
and Tyr308 of TM7 ( all known from point mutation studied9b), and with Gln105 
and Leu102 of TM2. The major interaction with Gln105 is hydrogen bond for-
mation to the 14-hydroxy group of 1 (NH⋅⋅⋅O distance is 0.22 nm). It was found 
earlier17a that the 14-hydroxy group plays an important role in δ-selectivity and 
the binding potency of some δ-selective ligands. On the other hand, it is generally 
believed16 that the residues at the top of TM6 and TM7 form a hydrophobic 
pocket to accommodate the indolic moiety of 1. According to the docking results 
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presented here, this hydrophobic pocket is formed by Val297, Val296 (EC3) and 
Leu300 (TM7) (known from point-mutation studies) and by the Ala195 and 
Val196 of EC2. 
The four derivatives of 1, ligands 2–5, differ in their experimentally deter-
mined binding constants, Table II. While the N-methyl derivative, 2, has a bind-
ing affinity towards the δ-receptor comparable to that of 1, the N-benzyl, N-cy-
clohexylmethyl and N-cyclohexylethyl derivatives (3, 4 and 5, respectively) are 
far less efficient. The docking results are in agreement with the experimental 
findings. The preferred conformations of 2 and 3 overlap in the binding pocket 
with the preferred conformation of 1, Fig. 2, but their binding energies (–38.4 
and –35.4 kJ/mol, respectively) are high relative to that of 1. The other two de-
rivatives, 4 and 5, cannot even adopt the preferred conformation characteristic for 
naltrindoles. It seems that the size of the pocket, surrounded by the amino-acid 
residues Leu102 and Gln105 of TM2 and Ile304 and Tyr308 of TM7 is too small 
to accommodate voluminous alkyl groups. Therefore any modification of the N-
alkyl part of the ligand will be limited by the size of the modified group. 
TABLE II. Experimental binding constants, Ki and IC50  
Compound 
δ-Receptor 
Ki / nM IC50 / nM 
1 0.22±0.13a, 0.04b – 
2 0.9±0.2a – 
3 115±32b – 
4 94.5±13.6b – 
5 181±35b – 
6 0.40±0.3a – 
7 19.0±2.0a – 
8 21.8±7.0a – 
9 4.5±0.5a – 
10 41.0±4.0a – 
11 218±33a – 
12 15.2c 56.5±3.10d 
13 4.12c 3.50±0.39d 
14 – 660.1±160.2e 
15 – 5.6±1.5e 
16 – >1000e 
17 – 6.2±0.6e 
aRef.17; bRef.18; cRef.19; dRef.20; eRef.21 
The other group of studied compounds was the ligands obtained by the 
opening of the 4,5-bridge in either 1 or 2. The in this way created 3-hydroxy-4- 
-methoxyindomorphinans (6 and 9), 3,4-dimethoxyindomorphinans (7 and 10) 
and 3-methoxy-4-hydroxyindomorphinans (8 and 11) show reduced binding po-
tency towards the δ-receptor compared to 1 and 2. This reduction in binding po-
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tency is small for 6 and 9 but increased in the case of the 3-methoxy compounds. 
Differences in affinity at a δ-receptor were earlier assigned17b to a shift in the 
relative position of the indole. The present docking study showed that this shift is 
small, less than 0.15 nm, Fig. 3. The reduced binding affinity may also be due to 
the presence of the 4-hydroxyl and the lack of a 3-hydroxyl group.17b However, 
the preferred conformations of compounds 6–11 do not allow a 3-hydroxy group 
to form any hydrogen bond or other important electrostatic interaction. When the 
3-hydroxyl group is replaced by a methoxy group, a steric clash occurs with 
Ile215 of TM5. Therefore, the reduced affinity of the ligands 7, 8, 10 and 11 for 
the δ-receptor may be due to steric interactions. This suggests that voluminous 
groups at the position 3 are unlikely to improve binding properties of indolomor-
phinans. 
The study of stereoisomers and their interactions with a particular receptor 
may be very useful. Two pairs of enantiomers were studied: the (+) and (–) forms 
of 3-[(2S,6R)-1,2,3,4,5,11-hexahydro-3-methyl-2,6-methano-6H-azocino[4,5-
b]indol-6-yl]phenol (compounds 14 and 15), and their 2-phenylethyl analogs 16 
and 17. The two enantiomers in both compounds have noticeably different 
binding affinities towards the δ-receptor.21 The (–) form (15 and 17) in both 
compounds binds better to the receptor. According to docking studies, this is the 
consequence of different preferred conformations of the (+) and (–) ligands in the 
binding pocket of the receptor. Compound 15 overlaps 1, Fig. 4, and has most of 
the major interactions with the receptor: the protonated nitrogen forms a salt 
bridge with Asp128, the phenolic group interacts with the amino acids at the be-
ginning of the EC3 loop, while the aromatic (indolic) group interacts with 
Tyr129 of TM3 and with Thr211 and Ile215 of TM5. Compound 14 cannot adopt 
this preferred conformation. The picture is less clear for compounds 16 and 17, 
where the flexible molecule can adopt a number of different conformations. The 
only explanation for the higher binding potency of 17 over 16 is the confor-
mation of 17 which partially overlaps the preferred conformation of compound 
13, known to have high binding potency, Fig. 5, Table II. Compound 16 cannot 
adopt a similar conformation. The noticeable difference in binding affinity to-
wards the opioid δ-receptor of SNC80, (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dime-
thyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide and its enantiomer19 
was explained earlier22 by the inability of the enantiomer to achieve the three 
important interactions with the receptor. SNC80 (Ki = 0.181 nM) has a higher af-
finity for the cloned human δ-receptor than its enantiomer (Ki = 218 nM).19 On 
the contrary, the αS,2S,5R diastereoisomer of SNC80, compound 12, has lower 
affinity for the cloned human δ-receptor than the enantiomer, 13. According to 
the docking results, this may also be explained by the classic “three point theo-
ry”. Compound 13 in its preferred conformation has a protonated nitrogen close 
to Asp128 (TM3) and forms a salt bridge. The NEt2 groups are located close in 
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the hydrophobic pocket at the beginning of EC3. The 3-methoxybenzyl group 
points toward Trp274 and His278 of TM6, Fig. 5. These ligand interactions with 
TM6 may be the major difference between antagonists and agonists and the key 
process in receptor activation. It was suggested earlier that movement of helices 
TM3, TM6 and TM7 is essential for activation of rhodopsin23 and the human δ-
receptor.3b It was also suggested24 that the 3-methoxy group was metabolized to 
a 3-hydroxyl group and that the analgesic activity was performed partially 
through this hydroxyl group.24 Compound 12, on the contrary, cannot adopt this 
favorable conformation and has only weak interactions with the receptor, about 
100 times weaker that SNC80. 
 
Fig. 4. Ligands 1 (yellow) and 15 (blue) 
in the binding pocket. 
Fig. 5 Ligands 13 (green) and 17 (orange) 
in the binding pocket. 
CONCLUSIONS 
An automated docking procedure was applied in order to determine the pre-
ferred conformations of a series of δ-opioid receptor selective ligands in the bind-
ing pocket of the receptor. The quality of the receptor-ligand complexes was es-
timated based on their binding energies and the ability to reproduce point muta-
tion experimental data. The following results are believed to assist in synthesis of 
new δ-selective ligands with a high binding potency. The preferred naltrindole 
conformation was found to be similar to the one suggested earlier,16 Fig. 2. The 
voluminous N-alkyl groups in compounds 1–5 are expected to reduce the binding 
potency by preventing the ligand from adopting the preferred conformation in the 
binding pocket. Voluminous groups replacing the hydroxyl group in the 3-hyd-
roxybenzyl fragment of naltrindole analogs, 6–11, reduce the binding potency 
due to unfavorable steric interactions with the receptor. Ligand interactions with 
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the amino acids at the beginning of EC3 are essential for ligand binding. The 
docking of two diastereoisomers, 12 and 13, of the potent δ-opioid ligand SNC80 
confirmed the preferred binding conformation of this compound proposed ear-
lier,22 and the major ligand–receptor interactions: protonated nitrogen interacting 
with Asp128 of TM3, hydrophobic groups interacting with EC3 and the phenolic 
group interacting with TM6 and TM5. 
Acknowledgments. This work was supported by the Ministry of Science and Technolo-
gical Development of the Republic of Serbia. 
И З В О Д  
НЕОПХОДНИ ЕЛЕМЕНТИ СТРУКТУРЕ ЗА ЛИГАНДЕ δ-ОПИОИДНОГ РЕЦЕПТОРА 
ВУК И. МИЋОВИЋ1, МИЛОВАН Д. ИВАНОВИЋ2,3 и ЉИЉАНА ДОШЕН-МИЋОВИЋ2,3 
1Institut za op{tu i fizi~ku hemiju, Beograd, 2Hemijski fakultet, Univerzitet u Beogradu, Student-
ski trg 12–16, Beograd i 3IHTM, Centar za hemiju, Univerzitet u Beogradu, Wego{eva 12, Beograd 
δ-Опиоидни рецептор је осетљив на геометрију лиганада. Да би се олакшала синтеза 
нових δ-селективних опиоидних лиганада, у раду су испитивани елементи њихове структуре 
који су неопходни за ефикасно везивање. Коришћен је аутоматизовани докинг поступак са 
флексибилним лигандом да би се симулирало везивање 17 δ-селективних једињења за δ-ре-
цептор. Нађено је да волуминозне N-алкил групе смањују ефикасност везивања деривата 
налтриндола тако што спречавају ова једињења да заузму конформацију погодну за вези-
вање. Ово је потвђено енантиоспецифичним везивањем хиралних једињења код којих само 
један енантиомер има оријентацију сличну налтриндолу у везујућем месту. Волуминозне 
групе које замењују 3-хидрокси групу код аналога налтриндола смањују ефикасност вези-
вања због неповољних стерних интеракција са рецептором. Начин везивања два диjастерео-
изомера ефикасног δ-опиоидног лиганда SNC80, потврђује најбољу конформацију за вези-
вање и најважније рецептор–лиганд интеракције. 
(Примљено 22. октобра 2008, ревидирано 28. маја 2009) 
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